Abstract
In 2019, Anvisa authorized the commercialization of products and medicines based on Cannabis sativa L. in Brazil. The plant is recognized for its medicinal benefits, thanks to its hytocannabinoids and terpenoids content. Among non-psychoactive substances, cannabidiol (CBD) is particularly valuable from a pharmaceutical perspective due to its antioxidant, antiinflammatory, antibiotic, neur…